Drug Trial Radar · NCT05210790
A Study of Rusfertide in Adults With Polycythemia Vera (PV)
Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
293
Actual
Start
Apr 11, 2022
Primary completion
Feb 21, 2025
Study completion Aug 31, 2028
Sponsor
- Lead sponsor
- Protagonist Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Polycythemia vera (PV) is a long-term condition in which the bone marrow makes too many red blood cells (RBCs). Bone marrow is the soft tissue inside the large bones where blood cells are made. When there are too many RBCs, called erythrocytosis, the blood can become thicker and move less easily through blood vessels and organs. This can raise the risk of blood clots (thrombosis) in veins or arteries. Sometimes, these clots can be life-threatening and may cause a stroke or heart attack. Treatment aims to keep the percentage of RBCs in the blood (hematocrit) in a safe range. For adults with PV, this means keeping the hematocrit below 45%. This helps lower the blood thickness and the risk of thrombosis. PV can also be linked to low iron levels (iron deficiency), because the body uses iron to make more RBCs. Many people with PV are treated with blood removal (phlebotomy) to lower RBC levels in the blood. This can worsen the iron deficiency, because each blood removal also takes iron out of the body. Rusfertide is a medicine that lowers the amount of iron available in the blood. It works like hepcidin, a natural hormone that helps control iron levels in the body. By limiting iron available for RBC production, rusfertide may help keep hematocrit below 45% and may improve symptoms. It may also reduce, or even remove, the need for phlebotomy in people. The main aim of this study is to check how well rusfertide works compared with placebo to lower the number of phlebotomies. A placebo looks like rusfertide but does not have any medicine in it. Other aims are to learn how safe rusfertide is compared with placebo and to understand how well it works to reduce the need for phlebotomy and to keep hematocrit levels under control. The study also wants to learn how rusfertide moves through the body (pharmacokinetics) and how it affects the body (pharmacodynamics or PD). This study has 4 parts that follow each other: * In part 1a, participants will receive either rusfertide or placebo. * In part 1b, all participants will receive rusfertide. * In part 2, participants can continue to receive rusfertide if they benefit from treatment with rusfertide. * Part 3 will include participants who finish Part 2 and still benefit from rusfertide. During the study, participants will visit the study clinical several times at fixed timepoints.
Conditions
- Polycythemia Vera
Interventions
RusfertideDrug
Rusfertide SC injection
PlaceboDrug
Rusfertide-matching placebo SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1a: Percentage of Participants Who Achieved ResponseTime frame: From Weeks 20 to 32
Locations
184 sites in 20 countries. Site status is shown where the registry gives one.
Infirmary Cancer Care
Mobile, Alabama
Palo Verde Hematology-Oncology
Glendale, Arizona
City of Hope Medical Center, Duarte
Duarte, California
California Cancer Associates for Research and Excellence - Fresno
Fresno, California
Marin Cancer Care
Greenbrae, California
City of Hope Medical Center, Lenner
Irvine, California
University of California, San Diego (UCSD) - Moores Cancer Center
La Jolla, California
University of California, Los Angeles (UCLA) - Medical Center
Los Angeles, California
Stanford University
Palo Alto, California
Pomona Valley Hospital Medical Center
Pomona, California
Sharp Memorial Hospital
San Diego, California
University of California, San Francisco
San Francisco, California
City of Hope Medical Center, Upland
Upland, California
Rocky Mountain Cancer Centers
Aurora, Colorado
University of Colorado - Aurora Cancer Center
Aurora, Colorado
Rocky Mountain Cancer Centers - Boulder
Boulder, Colorado
Rocky Mountain Cancer Centers
Colorado Springs, Colorado
Rocky Mountain Cancer Centers
Colorado Springs, Colorado
Rocky Mountain Cancer Centers
Denver, Colorado
Rocky Mountain Cancer Centers
Lakewood, Colorado
Rocky Mountain Cancer Centers
Littleton, Colorado
Rocky Mountain Cancer Centers
Lone Tree, Colorado
Yale University School of Medicine - Yale Cancer Center
New Haven, Connecticut
BRCR Medical Center
Plantation, Florida
BayCare Suncoast Medical Clinic - Hematology/Oncology
St. Petersburg, Florida
Moffitt Cancer Center
Tampa, Florida
Northwestern Memorial Hospital
Chicago, Illinois
Northwestern Medicine Lake Forest Hospital
Lake Forest, Illinois
Northwest Oncology and Hematology
Rolling Meadows, Illinois
Orchard Healthcare Research Inc
Skokie, Illinois
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana
Mission Cancer & Blood
Des Moines, Iowa
University of Iowa Hospitals and Clinics
Iowa City, Iowa
University of Kansas Cancer Center
Kansas City, Kansas
Pontchartrain Cancer Center
Covington, Louisiana
Pontchartrain Cancer Center
Hammond, Louisiana
American Oncology Partners of Maryland PA (Center for Cancer & Blood Disorders)
Bethesda, Maryland
University of Michigan
Ann Arbor, Michigan
Cancer Care Specialists
Reno, Nevada
Memorial Sloan Kettering Cancer Center - BASKING RIDGE
Basking Ridge, New Jersey
Showing 40 of 184 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.